Evidence map›Paper›PMID 35403164›Full record

ArticleCancer diagnosis & prognosis

Vein-first Lobectomy for Lung Cancer Assessed According to the Status of Clustered Circulating Tumour Cells.

Noriyoshi Sawabata, Shigeru Nakane, Daiki Yoshikawa, Takashi Watanabe, Takeshi Kawaguchi, Noriko Ouji-Sageshima, Keiji Kushibe, Toshihiro Ito

Abstract read
In one paragraph

Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Noriyoshi SawabataDepartment of Thoracic and Cardio-Vasucilar Surgery, Nara Medical University, Kashihara, Japan.
Shigeru NakaneRespiratory Disease Center, Hoshigaoka Medical Center, Hirakata, Japan.
Daiki YoshikawaDepartment of Thoracic and Cardio-Vasucilar Surgery, Nara Medical University, Kashihara, Japan.
Takashi WatanabeDepartment of General Thoracic Surgery, Nara Prefectural General Medical Center, Nara, Japan.
Takeshi KawaguchiDepartment of Thoracic and Cardio-Vasucilar Surgery, Nara Medical University, Kashihara, Japan.
Noriko Ouji-SageshimaDepartment of Immunology, Nara Medical University, Kashihara, Japan.
Keiji KushibeDepartment of General Thoracic Surgery, Nara Prefectural General Medical Center, Nara, Japan.
Toshihiro ItoDepartment of Immunology, Nara Medical University, Kashihara, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aim: Vein-first lobectomy (VFL) in lung cancer might reduce shedding of circulating tumour cells (CTCs). This study assessed the clinical significance of VFL. Patients and Methods: Lung cancer patients undergoing lobectomy and CTC testing were evaluated. The primary evaluation item was postoperative clustered CTC detection, and the secondary outcome measures were the 2-year overall survival and recurrence-free survival rates according to the status of VFL and postoperative clustered CTC. Results: Eighty-six patients with similar backgrounds, except for lobe resection and pulmonary vein dissection time, showed postoperative clustered CTC identification rates of 43.8% and 37.9% in the VFL group (n=57) and no-VFL group (n=29), respectively. However, prognosis was not significantly different, although the presence of clustered CTC after surgery was a predictor of recurrence. Conclusion: The status of postoperative clustered CTC was similar regardless of VFL or not, although the detection of clustered CTC was a predictor of recurrence.

Indexed as

circulating tumour cellno-touch isolation techniqueoverall survivalrecurrence-free survivalVein-first dissection lobectomy

Identifiers

PMID35403164
PMCPMC8962860

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.